scholarly journals Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically

BMC Urology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Bin Yang ◽  
Haizhui Xia ◽  
Chuxiao Xu ◽  
Min Lu ◽  
Shudong Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumour Thrombus ◽  
Rhabdoid Differentiation ◽  
Sarcomatoid Differentiation

The impact of rhabdoid differentiation on prognosis in patients with grade 4 renal cell carcinoma.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 494-494
Author(s):  
Ben Yiming Zhang ◽  
John C. Cheville ◽  
Robert Houston Thompson ◽  
Stephen A. Boorjian ◽  
Christine M. Lohse ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Risk Of Death ◽  
Pathologic Features ◽  
Increased Risk ◽  
Grade 3 ◽  
Rhabdoid Differentiation ◽  
The Impact ◽  
Sarcomatoid Differentiation

494 Background: Renal cell carcinoma (RCC) with rhabdoid differentiation is thought to portend a poor prognosis, similar to RCC with sarcomatoid differentiation. Both rhabdoid and sarcomatoid differentiation are classified as grade 4 RCC based on the most recent International Society of Urological Pathology (ISUP) grading system. We sought to determine the prognostic value of rhabdoid differentiation in comparison to RCC with sarcomatoid differentiation, grade 4 RCC without rhabdoid or sarcomatoid differentiation, and grade 3 RCC. Methods: Using the Mayo Clinic Nephrectomy Registry, we identified 406 patients with ISUP grade 4 RCC and 1,758 patients with grade 3 RCC. A urologic pathologist reviewed all specimens to determine the presence of both rhabdoid and sarcomatoid differentiation. Associations of clinical and pathologic features with death from RCC were evaluated using Cox models. Results: Among the 406 grade 4 RCC tumors, 111 (27%) had rhabdoid differentiation and 189 (47%) had sarcomatoid differentiation, although only 28 (7%) demonstrated both rhabdoid and sarcomatoid differentiation. In multivariable analysis of grade 4 RCC tumors, the presence of rhabdoid differentiation was not associated with death from RCC (HR 0.95, p=0.75); in contrast, sarcomatoid differentiation was significantly associated with death from RCC (HR 1.63, p<0.001). Patients with RCC with rhabdoid differentiation were significantly more likely to die of RCC than patients with grade 3 RCC (HR 2.45, p<0.001) and grade 3 RCC with necrosis (HR 1.62; p<0.001). Conclusions: This study confirms that RCC with rhabdoid differentiation is appropriately classified as grade 4. However, unlike sarcomatoid differentiation, the presence of rhabdoid differentiation in grade 4 RCC is not associated with an increased risk of death from RCC. Therefore, rhabdoid and sarcomatoid differentiation should not be grouped together when assessing risk in a patient with grade 4 RCC.

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma

2007 ◽  
Vol 95 (4) ◽  
pp. 317-323 ◽  
Author(s):  
Cheol Kwak ◽  
Yong Hyun Park ◽  
Chang Wook Jeong ◽  
Hyeon Jeong ◽  
Sang Eun Lee ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Sarcomatoid Differentiation

Chromophobe renal cell carcinoma with sarcomatoid differentiation containing various heterologous components

2018 ◽  
Vol 68 (9) ◽  
pp. 524-529
Author(s):  
Toshiki Hyodo ◽  
Maki Kanzawa ◽  
Shigeo Hara ◽  
Kosuke Takahashi ◽  
Satoshi Ogawa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Chromophobe Renal Cell Carcinoma ◽  
Sarcomatoid Differentiation

scholarly journals Renal cell carcinoma with rhabdoid differentiation: A novel entity with immunohistochemical study

2016 ◽  
Vol 59 (4) ◽  
pp. 565
Author(s):  
AAil Divya ◽  
GSinai Kandheparkar Siddhi ◽  
RJoshi Avinash ◽  
DBhayekar Pallavi
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Immunohistochemical Study ◽  
Rhabdoid Differentiation

scholarly journals The importance of intraoperative transoesophageal monitoring when operating on renal cancers that involve the right atrium

2014 ◽  
Vol 96 (6) ◽  
pp. e18-e19 ◽  
Author(s):  
J George ◽  
K Grebenik ◽  
N Patel ◽  
D Cranston ◽  
S Westaby
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Right Atrium ◽  
Renal Cell ◽  
Transoesophageal Echocardiography ◽  
Cardiac Monitoring ◽  
Vascular Involvement ◽  
Tumour Thrombus ◽  
The Right

The surgical treatment of advanced renal cancers is challenging. Renal cell carcinoma is interesting in that it invades the vasculature and can extend up as far as the right atrium. Extension of tumour thrombus into the right atrium represents level IV disease, according to Robson staging. Transoesophageal echocardiography is useful for diagnostic purposes. It is also of great value for intraoperative cardiac monitoring and to confirm the extent of vascular involvement.

The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus

2004 ◽  
Vol 94 (1) ◽  
pp. 33-41 ◽  
Author(s):  
Michael L. Blute ◽  
Bradley C. Leibovich ◽  
Christine M. Lohse ◽  
John C. Cheville ◽  
Horst Zincke
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Surgical Management ◽  
Mayo Clinic ◽  
Renal Cell ◽  
Tumour Thrombus ◽  
Clinic Experience

scholarly journals Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

2020 ◽  
Vol 38 (1) ◽  
pp. 63-70 ◽  
Author(s):  
Bradley A. McGregor ◽  
Rana R. McKay ◽  
David A. Braun ◽  
Lillian Werner ◽  
Kathryn Gray ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Checkpoint Inhibitors ◽  
Progression Free Survival ◽  
Symptom Index ◽  
Multicenter Phase ◽  
Variant Histology ◽  
Sarcomatoid Differentiation

PURPOSE In this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ≥ 20% sarcomatoid differentiation. PATIENTS AND METHODS Eligible patients may have received previous systemic therapy, excluding prior bevacizumab or checkpoint inhibitors. Patients underwent a baseline biopsy and received atezolizumab 1,200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks. The primary end point was overall response rate (ORR) by RECIST version 1.1. Additional end points were progression-free survival (PFS), toxicity, biomarkers of response as determined by programmed death-ligand 1 (PD-L1) status, and on-therapy quality-of-life (QOL) metrics using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 and the Brief Fatigue Inventory. RESULTS Sixty patients received at least 1 dose of either study agent; the majority (65%) were treatment naïve. The ORR for the overall population was 33% and 50% in patients with clear cell RCC with sarcomatoid differentiation and 26% in patients with variant histology RCC. Median PFS was 8.3 months (95% CI, 5.7 to 10.9 months). PD-L1 status was available for 36 patients; 15 (42%) had ≥ 1% expression on tumor cells. ORR in PD-L1–positive patients was 60% (n = 9) v 19% (n = 4) in PD-L1–negative patients. Eight patients (13%) developed treatment-related grade 3 toxicities. There were no treatment-related grade 4-5 toxicities. QOL was maintained throughout therapy. CONCLUSION In this study, atezolizumab and bevacizumab demonstrated safety and resulted in objective responses in patients with variant histology RCC or RCC with ≥ 20% sarcomatoid differentiation. This regimen warrants additional exploration in patients with rare RCC, particularly those with PD-L1–positive tumors.

Sign in / Sign up

Export Citation Format

Share Document